Hunting for B + → K + τ + τ - imprints on the B + → K + µ + µ - dimuon spectrum.

We investigate the possibility of indirectly constraining the B + → K + τ + τ - decay rate using precise data on the B + → K + µ + µ - dimuon spectrum. To this end, we estimate the distortion of the spectrum induced by the B + → K + τ + τ - → K + µ + µ - re-scattering process, and propose a method to simultaneously constrain this (non-standard) contribution and the long-distance effects associated to hadronic intermediate states. The latter are constrained using the analytic properties of the amplitude combined with data and perturbative calculations. Finally, we estimate the sensitivity expected at the LHCb experiment with present and future datasets. We find that constraints on the branching fraction of O ( 10 - 3 ) , competitive with current direct bounds, can be achieved with the current dataset, while bounds of O ( 10 - 4 ) could be obtained with the LHCb upgrade-II luminosity.

Pregnancy and renal transplantation: a case report of the risk of antibody induction against partner antigens.

Renal transplantation has provided women of childbearing age with increased fertility and the possibility of successful pregnancy outcomes. Approximately 14,000 births among women with transplanted organs have been reported worldwide, but pregnancy complications have been frequent: spontaneous or therapeutic abortion, preterm birth, low birth weight, and intrauterine growth restriction. Herein we have described a case of an acute rejection episode in a renal transplant recipient, occurring 6 months after successful delivery, despite the fulfillment of all European best practice guidelines criteria and the maintenance of adequate immunosuppression. Our case demonstrated that even a presumably low-risk patient can face worsening of renal function during or after pregnancy. Acute immune activation is uncommon but may occur in late-onset fashion. Despite adequate levels of maintenance immunosuppression, there is a risk of developing antibodies against the partner or the donor, causing acute renal immune damage.

Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation.

BACKGROUND: Occult hepatitis B virus (HBV) infection can be defined as the long-lasting persistence of viral genomes in the liver tissue, and sometimes also in the serum at low levels of viremia in individuals with undetectable HBV surface antigen (HBsAg). Viral replication can be reactivated by immunosuppressive therapies or immunologic diseases, leading to the development of typical hepatitis B. METHODS: All patients on the waiting list for renal transplantation at the only 2 transplant centers in our region (Piemonte, Italy) were checked for the presence of occult HBV infection by an highly sensitive quantitative HBV-DNA polymerase chain reaction (PCR) assay (nested PCR); the only exclusion criterion was HBsAg-positivity. The enrollment lasted from October 1, 2006, to May 31, 2007. The prospective follow-up will continue for 5 years. RESULTS: HBV-DNA sequences were detected in blood samples from 10 of 300 cases examined (3.3%), being more frequent among Asian (1/3; 33.3%) and African (1/16; 6.25%) subjects as compared with the Caucasians (8/281; 2.8%; P = .011), among anti-hepatitis C virus (HCV) positive versus HCV negative patients (3/32 [9.3%] vs 7/268 [2.6%]; P = .004) and mainly among patients with a previous history of overt liver diseases (3/22 [14%] vs 7/278 [2.5%]; P = .019). HBV-DNA sequences became undetectable at 1 month after renal transplantation in 3 patients; the follow-up is in progress for these and the other patients. CONCLUSION: Occult HBV infection occurs in patients undergoing renal transplantation. Longer observation and prospective studies will clarify the clinical impact of this occult infection on transplant outcomes and the possibility of viral reactivation related to immunosuppressive therapy.

Quality of life in renal transplant patients over 60 years of age.

Kidney transplantation not only drastically improves the life-expectancy of hemodialyzed patients, but it also affords psychological and social advantages with improvements in short- and long-term personal and working lives. Quality of life (QoL) is one of the parameters of psychological well-being. There is an improvement of QoL from pre- to posttransplant, but it is not to the level of healthy samples. The aim of this study was to examine QoL in older renal transplant recipients. All recipients older than age 60 were included, with a minimum follow-up of 12 months. To measure QoL, the nationally standardized ShortForm-36 (SF-36) questionnaire was administered. The SF-36 responses by our patients were compared with national age- and gender-appropriate norms, and also between genders. The enrolled population included 19 women (36.5%) and 33 men (63.5%), with a mean age of 66.8 years (range, 60-73 years). Enrolled women reported significant limitations compared to gender- and age-matched norms in social activities (42.11 vs 70.58), perception of pain (22.11 vs 59.17), and general health perception (39.58 vs 48.69). Enrolled men reported significant limitations compared to gender- and age-matched norms in social activities (46.59 vs 78.35), perception of pain (18.18 vs 73.62), psycho-physical energy (50.15 vs 67.88), and general health perception (37.33 vs 61.66). No significant differences were noted between the genders. This study clearly showed how the psychological state was not as good as the clinico-physical recovery following renal transplantation in older recipients.

[Antiviral prophylaxis and pre-emptive therapy for the prevention of Cytomegalovirus infection in renal transplant recipients: guideline from the Italian Society of Nephrology]. / Profilassi con farmaci antivirali e pre-emptive therapy per la prevenzione dell'infezione da Citomegalovirus nel trapianto di rene: Linea Guida.

BACKGROUND: The current 3rd edition of the Italian Society of Nephrology guidelines has been drawn up to summarize evidence of key intervention issues on the basis of systematic reviews (SR) of randomized trials (RCT) or RCT data only. In the present guideline, evidence of antiviral prophylaxis and pre-emptive treatment for preventing cytomegalovirus (CMV) infection in kidney transplant recipients is presented. METHODS: SR of RCT and RCT on antiviral prophylaxis and pre-emptive treatment for CMV infection in kidney transplant recipients were identified referring to a Cochrane Library and Renal Health Library search (2005 update). RESULTS: Evidence from 4 SR of RCT was gathered to address this issue. Methodological quality of available RCT included in these SR was suboptimal. Antiviral prophylaxis is associated with a significant reduction in the risk of CMV infection and all-cause mortality in CMV-negative and CMV-positive renal transplant recipients from CMV-positive donors, regard-less of the immunosuppressive treatments used (evidence from SR). Pre-emptive therapy has been found to be effective in preventing CMV disease but not all-cause mortality in these patients, even if evidence is less satisfactory compared to data on antiviral prophylaxis (evidence from SR). There is insufficient evidence of conclusive recommendations on treatment of CMV-negative recipients of renal transplants from CMV-negative donors. CONCLUSION: In kidney transplant patients current available evidence supports the hypothesis that antiviral prophylaxis and pre-emptive therapy are effective in preventing CMV disease; but antiviral should be the treatment of choice. Further studies are necessary on the treatment of CMV-negative recipients from CMV-negative donors.

[Malignant neoplasia and kidney transplantation. Retrospective analysis of data on the population having kidney transplantation with de novo neoplasia in the setting of the AIRT]. / Trapianto renale e neoplasie. Analisi retrospettiva dei dati relativi alla popolazione dei trapiantati di rene affetti da neoplasie de novo in ambito AIRT.

BACKGROUND: In transplanted patients undergoing immunossuppressive therapy the incidence of malignant neoplasia is 3-4 times higher than in the general population. Aim of the present study was to evaluate the prevalence of different tumours and the links between modulation of immunosuppressive therapy and patient and graft survival. PATIENTS: We evaluated 2029 kidney-transplanted patients from four Transplant Centres (Bari, Bologna, Modena, Novara) belonging to the Associazione InterRegionale Trapianti (AIRT). RESULTS: The incidence of neoplastic disease after transplantation was 3.9% in our population with a median time between transplantation and clinical onset of 23 months. We demonstrated a significant difference in the geographical distribution of different tumours. We did not observe any correlation with specific immunosuppressive drugs. Finally, dramatic reduction of the immunosuppression levels did not modify either the patients' or the graft's survival. CONCLUSIONS: Several factors can influence the post-transplant onset of neoplastic diseases with immunosuppressive therapy playing a pivotal role. The implementation of a National Registry would be the first step in an attempt to optimise immunosuppression in this particular group of patient's.

Monitoring of central venous dual-lumen catheter placement in haemodialysis: improvement of a technique for the practising nephrologist.

Mismanagement in the placement of central venous catheter (CVC) may occur in up to 20% of cases. The catheter can be inadvertently placed in the contralateral brachiocephalic vein, the ipsi or contralateral internal jugular vein, and usually a thoracic radiograph is necessary to evaluate its location. We propose a technique first described by Serafini et al. to establish the position of a CVC by endocavitary electrocardiography (EC-ECG) and its employment in a large number of uraemic patients requiring haemodialysis. This technique uses the tip of the CVC as reference lead in a standard electrocardiograph. The best employment of this technique has been obtained by echotomographic visualization of the internal jugular vein executed just before transcutaneous puncture of the vessel. For 13 months we have successfully applied this technique in CVC placement in 81 patients requiring haemodialysis. In our opinion this method is a safe and simple technique that avoids the need for thoracic radiographs and time lost waiting for radiographs that prolong the start of the haemodialysis session. According to our experience, we confirm that the EC-ECG technique provides a method for ensuring compliance with Food and Drug Administration guidelines regarding catheter tip location in uraemic patients.

Monitoring of central venous dual-lumen catheter placement in haemodialysis: improvement of a technique for the practising nephrologist.

Mismanagement in the placement of central venous catheter (CVC) may occur in up to 20% of cases. The catheter can be inadvertently placed in the contralateral brachiocephalic vein, the ipsi or contralateral internal jugular vein, and usually a thoracic radiograph is necessary to evaluate its location. We propose a technique first described by Serafini et al. to establish the position of a CVC by endocavitary electrocardiography (EC-ECG) and its employment in a large number of uraemic patients requiring haemodialysis. This technique uses the tip of the CVC as reference lead in a standard electrocardiograph. The best employment of this technique has been obtained by echotomographic visualization of the internal jugular vein executed just before transcutaneous puncture of the vessel. For 13 months we have successfully applied this technique in CVC placement in 81 patients requiring haemodialysis. In our opinion this method is a safe and simple technique that avoids the need for thoracic radiographs and time lost waiting for radiographs that prolong the start of the haemodialysis session. According to our experience, we confirm that the EC-ECG technique provides a method for ensuring compliance with Food and Drug Administration guidelines regarding catheter tip location in uraemic patients.